Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Not yet recruiting 5Recruiting 4Terminated 2Completed 1

Sponsor Class

OTHER 5

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Gynecologic 4Dermatologic 1

Conditions

Ovarian Neoplasms 2Cervical Cancer Metastatic 2Melanoma 1

Interventions

Specimen Handling 79Bevacizumab 66Drug Therapy 65Cisplatin 64Carboplatin 63Magnetic Resonance Spectroscopy 61Radiotherapy 57Cyclophosphamide 55Gemcitabine 54pembrolizumab 53Oxaliplatin 50Capecitabine 50toripalimab 42Paclitaxel 41tislelizumab 40Standard of Care 40Biopsy 37fludarabine 36Fluorouracil 35venetoclax 33Injections 33Blood Specimen Collection 31Immune Checkpoint Inhibitors 30anlotinib 29Nivolumab 29Surgical Procedures, Operative 28Irinotecan 27Docetaxel 27Dexamethasone 27Leucovorin 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Not yet recruiting × famitinib × 1 year × Clear all
NCT07517653 2026-04-08

Neoadjuvant SHR-1701 Plus Famitinib With Response-guided Adjuvant Therapy in Resectable Mucosal Melanoma

Shanghai Zhongshan Hospital

Phase 2 Not yet recruiting
70 enrolled
Dermatologic

Melanoma

NCT07382713 2026-02-03

Fluzoparib Plus Famitinib Maintenance After First-Line Platinum Response in Advanced Ovarian Cancer

The First Affiliated Hospital of Soochow University

Phase 2 Not yet recruiting
43 enrolled
Gynecologic

Ovarian Neoplasms

NCT07355010 2026-01-21

A Randomized, Open-label, Double-cohort Study of Fluzoparib Combined With Famitinib Malate or SHR-1701 for Neoadjuvant Therapy in Patients With Advanced Ovarian Cancer

Tongji Hospital

Phase 2 Not yet recruiting
104 enrolled
Gynecologic

Ovarian Neoplasms

NCT07266350 2025-12-05

A Non-interventional Registration Study of Monotherapy or Combination Regimens Based on Camrelizumab or Famitinib for the Treatment of Cervical Cancer

Chongqing University Cancer Hospital

Not yet recruiting
1,300 enrolled
Gynecologic

Cervical Cancer Metastatic

NCT07143292 2025-11-18

A Prospective, Randomized, Parallel Trial of Famitinib Malate at Different Doses Combined With Camrelizumab for the Treatment of Recurrent and Metastatic Cervical Cancer

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2 Not yet recruiting
120 enrolled
Gynecologic

Cervical Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡